Heart failure & cardiomyopathies
Brain Natriuretic Peptide (BNP) and NT-proBNP Thresholds for the Assessment of Prognosis in Patients Without Heart Failure
Performance · All-cause mortalityResult — go to the resultHazard ratio 2.44 95% CI 1.32–4.53Authors' conclusion
We here describe sex-specific BNP/NT-proBNP thresholds that allow prediction of impaired survival in patients without heart failure, independent of traditional cardiovascular risk factors.
Study context
- Population
- Patients without known HF or elevated BNP/NT-proBNP, Essen CAD registry (age 62.9 ± 12.5 years, 71% male, 68% with CAD)169 deaths
- Participants
- 3,690 patients
- Comparison
- BNP/NT-proBNP above vs below sex-specific thresholds
- Outcome
- All-cause mortality
- Follow-up
- Mean 2.6 ± 3.4 years (median 1.2 [IQR: 0.4-2.88])
Methodological detailsregistry-based, derivation and validation, random split into derivation and validation cohorts, ROC analysis with Youden's J index, univariate and multivariable Cox regression
- Registry-based, derivation and validation
- Random split into derivation and validation cohorts
- ROC analysis with Youden's J index
- Univariate and multivariable Cox regression
Performance
As reported in the abstract
mean follow-up 2.6 ± 3.4 years
Hazard ratio
2.44
95% CI 1.32–4.53
P = 0.005
BNP/NT-proBNP abovevs below sex-specific thresholds
HR 2.44 (95% CI 1.32–4.53); P = 0.005
- Predictive value confirmed in validation cohort
- HR: 2.78 [95% CI: 1.26-6.14], P = 0.01
Original publication
BNP and NT-proBNP Thresholds for the Assessment of Prognosis in Patients Without Heart Failure. JACC Adv. Published 16 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →